Creatine monohydrate in muscular dystrophies: A double-blind, placebo- controlled clinical study

Neurology

Volumn 54, Issue 9, 2000, Pages 1848-1850

  Walter, M C ^a   Lochmuller H ^b   Reilich, P ^b   Klopstock, T ^b   Huber, R ^b   Hartard, M ^b   Hennig, M ^b   Pongratz, D ^b   Muller Felber W ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Creatine; Dietary supplement; Muscular dystrophy; Therapy

Indexed keywords

CREATINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0343022262     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.9.1848     Document Type: Article

References (10)

1. Kissel JT, Mendell JR. Muscular dystrophy: historical overview and classification in the genetic era. Semin Neurol 1999; 15:5-7.
2. Bosco C, Tihanyi J, Pucspk J, et al. Effect of oral creatine supplementation on jumping and running performance. Int J Sports Med 1997;18:369-372.
3. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-1509.
4. Tarnopolsky MA, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857.
5. Soueidan SA, Dalakas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
6. Younkin DP, Berman P, Sladky J, Chee C, Bank W, Chance B. 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology 1987;37:165-169.
7. Kemp GJ, Taylor DJ, Dunn JF, Frostick SP, Radda GK. Cellular energetics of dystrophic muscle. J Neurol Sci 1993;116: 201-206.
8. 2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 1998;439:357-362.
9. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
10. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43:520-527.